Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

Last updated: July 25, 2023
Sponsor: BAMF Health
Overall Status: Active - Recruiting

Phase

1

Condition

Prostate Cancer, Early, Recurrent

Prostate Cancer

Prostate Disorders

Treatment

illuccix 68Ga-PSMA-11 Total Body PET-CT

Clinical Study ID

NCT05558956
BAMF-2022-03
  • Ages > 18
  • Male

Study Summary

Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Provision of signed and dated informed consent form
  2. Male ≥ 18 years of age
  3. Patients meeting clinical need for Illuccix PET scan:
  4. Patients with suspected metastasis who are candidates for initial definitivetherapy
  5. Patients with suspected recurrence based on elevated serum prostate-specificantigen (PSA) level
  6. Patient is physically able to lay flat for the PET-CT procedure

Exclusion

Exclusion Criteria:

  1. Assessment by the Investigator as unable or unwilling to comply with the requirements ofthe protocol.

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: illuccix 68Ga-PSMA-11 Total Body PET-CT
Phase: 1
Study Start date:
November 01, 2022
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • BAMF Health

    Grand Rapids, Michigan 49503
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.